2012 CSHL Neurodegenerative Diseases Conference

2012年CSHL神经退行性疾病会议

• 批准号: 8458763
• 负责人: DAVID J. STEWART
• 金额: $ 2.3万
• 依托单位: COLD SPRING HARBOR LABORATORY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-26 至 2013-09-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8458763
• 关键词: Address; Alzheimer' s Disease; Amyotrophic Lateral Sclerosis; Biological Markers; Biology; Collaborations; Communities; Comorbidity; Coupled; Data; Development; Disease; Disease Progression; Ensure; Environment; Faculty; Future; Gene Silencing; Human; Immune; Industry; Information Dissemination; Institution; International; Knowledge; Laboratories; Lead; Metabolism; Molecular; Nationalities; Nerve Degeneration; Neurodegenerative Disorders; Parkinson Disease; Participant; Postdoctoral Fellow; Prevalence; Process; Public Health; RNA; Reagent; Research; Research Institute; Research Personnel; Risk Factors; Science; Scientist; Symptoms; Translational Research; abstracting; cost; data exchange; graduate student; innovation; lectures; meetings; multidisciplinary; novel; novel diagnostics; novel therapeutics; posters; prion-like; small molecule; stem; success; symposium; therapy design; unpublished works

DESCRIPTION (provided by applicant): This proposal seeks support for the biennial conference on Neurodegenerative Diseases, which will take place November 28-December 1, 2012, at Cold Spring Harbor Laboratory (CSHL). This meeting brings together scientists who investigate both basic and translational aspects of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. For many such disorders, steps in the disease processes remain unclear and thus biomarkers have not yet been identified. For other disorders, existing treatments are designed primarily to provide relief from symptoms, and do not address the underlying degenerative processes. Translational research is therefore needed to develop and validate novel diagnostic strategies as well as new therapeutics that might halt or stem disease progression, rather than simply alleviate symptoms. The conference will advance knowledge in neurodegeneration by providing a forum where scientists from distinct laboratories and institutions, both academic and from industry, can interact with each other. It will include sessions on prion-like neurodegeneration, risk factors an co-morbidities, RNA metabolism, glial biology, immune and small-molecule therapies, and gene inactivation strategies. For human studies utilizing new treatments for neurodegeneration to be informative, it is crucial that scientists who research different aspects of those treatments meet regularly in a setting like CSHL to exchange data and ideas. The 2012 CSHL meeting on Neurodegenerative Diseases will build on the successes of prior CSHL meetings to assemble an international gathering of scientists, discuss new developments in the field, and catalyze innovative research collaborations, all of which will ultimately accelerate the pace of discovery.

描述(由申请人提供)：本提案寻求对将于2012年11月28日至12月1日在冷泉港实验室(CSHL)举行的两年一度的神经退行性疾病会议的支持。这次会议汇集了研究阿尔茨海默病、帕金森氏病和肌萎缩侧索硬化症等神经退行性疾病的基本和翻译方面的科学家。对于许多这样的疾病，疾病过程中的步骤仍然不清楚，因此还没有确定生物标记物。对于其他疾病，现有的治疗方法主要是为了缓解症状，而不是解决潜在的退化过程。因此，需要进行转化研究，以开发和验证新的诊断策略以及可能阻止或阻止疾病进展的新疗法，而不是简单地缓解症状。这次会议将通过提供一个论坛，让来自不同实验室和机构的科学家，无论是学术上的还是工业界的，都可以相互交流，从而促进神经退化方面的知识。它将包括有关普恩样神经变性、风险因素和共病、RNA新陈代谢、胶质生物学、免疫和小分子治疗以及基因失活策略的会议。为了让利用新疗法治疗神经退行性变的人类研究具有信息量，研究这些疗法不同方面的科学家必须定期在CSHL这样的环境中会面，交流数据和想法，这一点至关重要。2012年CSHL神经退行性疾病会议将在之前CSHL会议的成功基础上，召集一次国际科学家会议，讨论该领域的新发展，并催化创新研究合作，所有这些最终都将加快发现的步伐。